Edwards Lifesciences (EW) to Release Quarterly Earnings on Tuesday

Edwards Lifesciences (NYSE:EWGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, April 26th. Analysts expect the company to announce earnings of $0.58 per share for the quarter. Edwards Lifesciences has set its Q1 guidance at $0.54-0.62 EPS and its FY22 guidance at $2.50-2.65 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Edwards Lifesciences (NYSE:EWGet Rating) last released its earnings results on Wednesday, January 26th. The medical research company reported $0.51 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.04). The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.34 billion. Edwards Lifesciences had a net margin of 28.73% and a return on equity of 26.53%. During the same period last year, the firm posted $0.50 EPS. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

EW opened at $119.28 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.08 and a quick ratio of 2.38. The stock’s 50 day simple moving average is $112.55 and its 200 day simple moving average is $115.09. The firm has a market cap of $74.11 billion, a price-to-earnings ratio of 49.91, a PEG ratio of 3.36 and a beta of 1.15. Edwards Lifesciences has a 1 year low of $87.32 and a 1 year high of $131.73.

In other news, VP Catherine M. Szyman sold 20,000 shares of the stock in a transaction that occurred on Monday, April 11th. The shares were sold at an average price of $122.04, for a total transaction of $2,440,800.00. Following the sale, the vice president now owns 27,569 shares in the company, valued at $3,364,520.76. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,050 shares of the stock in a transaction that occurred on Friday, January 28th. The shares were sold at an average price of $101.15, for a total transaction of $1,117,707.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 216,859 shares of company stock worth $24,110,684. Company insiders own 1.29% of the company’s stock.

Several large investors have recently bought and sold shares of EW. EverSource Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $29,000. Carroll Investors Inc purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $62,000. Zullo Investment Group Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $128,000. Crestwood Advisors Group LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $279,000. Finally, Forum Financial Management LP purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $334,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.

Several research analysts have recently issued reports on the stock. Citigroup cut their target price on shares of Edwards Lifesciences from $142.00 to $138.00 and set a “buy” rating on the stock in a report on Thursday, January 27th. Credit Suisse Group raised their target price on shares of Edwards Lifesciences from $131.00 to $144.00 and gave the stock an “outperform” rating in a report on Friday, January 7th. Raymond James cut their target price on shares of Edwards Lifesciences from $134.00 to $126.00 and set an “outperform” rating on the stock in a report on Thursday, January 27th. Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, January 27th. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Five analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus price target of $127.52.

Edwards Lifesciences Company Profile (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Recommended Stories

Earnings History for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.